Compare Merck & Co., Inc. (MRK) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.07. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Dividend Appreciation Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VIG | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $246.61 |
52-Week Low | $77.60 | $210.70 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
VIG trades at $240.11, down 0.79% with bearish technical signals from moving averages. The ETF maintains its dividend growth strategy, with a scheduled $1.00 dividend payment in June 2026. Recent news highlights institutional accumulation and comparisons with peer dividend ETFs, emphasizing VIG's defensive tech exposure and lower yield relative to competitors like SCHD.
Outlook remains cautious near-term due to technical pressure, but long-term dividend growth appeal persists for income-focused investors. Risks include interest rate sensitivity and yield competition, while institutional buying signals underlying confidence in the strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
